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Abstract
Background: Spirometry is the recommended method of evaluating pulmonary function when respiratory disease
is suspected in smokers. Nonetheless, no evidence exists of the usefulness of information obtained from this test as
a motivational strategy for smoking cessation. The primary objective of this study is to evaluate the effectiveness of
a motivational intervention based on spirometry results in achieving long-term smoking cessation.
Methods/Design: We propose a multicenter randomized clinical trial in the primary care setting. Study subjects:
We will recruit active smokers of both sexes, aged 35-70 years, with a cumulated smoking habit exceeding 10
packs/year and who consult for any reason with their primary care physician in the 20 health centers in the
province of Tarragona (Spain). Patients with a history of lung disease or who have undergone exploratory
measures of pulmonary function in the preceding 12 months will be excluded. All patients who agree to participate
will provide signed informed consent prior to their inclusion. A total of 1000 smokers will be consecutively randomized
to a control or intervention group (1:1). Intervention: Participants in both groups will receive brief (5-minute) health
counseling, in accordance with usual clinical practice. In a consultation lasting about 15 minutes, participants in the
intervention group will also receive detailed, personalized information about the results of a spirometry test and about
their lung age compared with their chronological age. Both groups will be followed up for 12 months. Main variables
and analysis: The main variable will be sustained smoking abstinence at 12 months after the intervention, as confirmed
by CO breath testing and urine cotinine test. Results will be analyzed based on intention to treat, using the chi-square
test and logistical regression if necessary to adjust for confounding variables.
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Discussion: We expect the rate of prolonged smoking abstinence in the intervention group will be at least 5 % higher
than in the control group. If this strategy proves effective, it could easily be included in the health promotion activities
offered in primary care settings.
Trial registration: ClinicalTrials.gov Identifier: NCT02153047. Registered on 28/05/2014
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Background
Diseases related to smoking frequently motivate patient
visits to health care settings in general and primary care
in particular. The magnitude of this health problem has
been widely studied and has been cited as the primary
preventable cause of mortality and morbidity in industri-
alized countries [1].
The available data indicate that the life expectancy of
habitual smokers is reduced by 15-20 years and approxi-
mately half will die as a consequence of their habit [2]. Tak-
ing this into account, it is surprising that the detrimental
health effects of smoking have so little social impact and
that smoking continues to be highly prevalent in our con-
text [3]. The health benefits of smoking cessation are well
established. With few exceptions, future risk is reduced
when smokers stop smoking and continue to decrease
while smoking abstinence is maintained. Progression of
smoking-related diseases is also slowed and life expectancy
improves by an average of 10 years [2]. For these reasons,
anti-smoking efforts in all contexts provide one of the
major central points around which many disease pre-
vention strategies revolve [3].
Treatment of the effects of smoking is an important
part of clinical practice and all health professionals need
to offer help and support to all smokers as part of usual
clinical practice [4]. Current guidelines base their rec-
ommendations on the “The 5As approach” (ask about
tobacco use, advise to quit, assess willingness to make a
quit attempt, assist in quit attempt, and arrange follow-up)
[5]. According to this model, the health professional who
knows the smoker’s motivation can choose the strategy that
has shown the greatest effectiveness in each situation.
Nonetheless, cigarette smoking is a highly addictive habit
that is difficult to give up, and achieving the motivation to
quit smoking is always a challenge. The available data sug-
gest that the majority of smokers are interested in quitting
[6] and that structured counseling by health care profes-
sionals is a motivational element for smoking cessation [7].
However, the rate of successful quit attempts is low and
does not usually exceed 10 % [8]. To increase the success
rate and accelerate change in smoking habits, it has been
suggested that instead of providing patients with general in-
formation about the detrimental heath effects of smoking,
they should be provided with personalized data on their
risk of acquiring a disease related to smoking [9].
Health concerns are among the reasons most often
cited as catalysts for smokers to make an attempt to quit
smoking [10, 11], and studies suggest that the more a
patient is aware of risks and benefits, the greater is their
motivation and likelihood of success [12]. Similar to
what occurs in smokers who have experienced smoking-
related complications, providing information about test-
ing for smoking-related harm or risks to health offers a
“teachable moment” that may facilitate behavioral change
[13]. In this respect, we can conceptually distinguish three
different feedback methods, depending on the approach
used to assess risk [14]: the first explores biomarkers of to-
bacco exposure, such as levels of urine cotinine or exhaled
carbon monoxide (eCO); the second gives information
about added risk of diseases related to a smoking habit,
such as genetic susceptibility to lung cancer; and the third
focuses on smoking-related harms such as the presence of
arterial plaque detected by echography or decreased pul-
monary function quantified by spirometry.
Spirometry is the recommended method of testing
pulmonary function to detect restricted respiratory flow
in smokers susceptible to chronic obstructive pulmonary
disease (COPD) [15]. The use of spirometry has become
generalized in primary care because it is a simple, nonin-
vasive procedure that provides valuable information about
pulmonary function and risk of premature death [16, 17]
that can increase motivation to quit smoking [18]. Some
years ago, the Lung Health Study showed that significantly
more participants included in an intensive smoking cessa-
tion program quit smoking, compared to those included
in the usual program [19]. Nonetheless, the experts in-
volved in the most recent report published by the U.S.
Preventive Services Task Force did not find sufficient evi-
dence to conclude that the use of spirometry improved
rates of smoking abstinence or affected the management
of the initial stages of COPD [20].
In recent years, various clinical trials have explored
the effect on smoking cessation of providing feedback
on spirometry results. The first study, published by
Segnan et al [21], included 923 smokers recruited by 44
primary care doctors in Italy. Participants were randomly
assigned to 4 different intervention groups: (a) a brief indi-
vidual intervention, (b) an intensive intervention with 4
follow-up sessions, (c) an intensive intervention and treat-
ment with nicotine gum, and (d) an intensive intervention
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and spirometry. The proportion of exsmokers at 12-month
follow-up was 4.8 %, 5.5 %, 7.5 %, and 6.5 %, respectively,
with no significant differences between the groups (RR:
1.19; 95 %CI: 0.62-2.30). Later, Buffels et al [22] published a
study that included 215 smokers attending 14 primary care
centers in Belgium who were prescribed treatment with
nicotine, bupropion, or both and were randomly assigned
to receive only a minimal intervention or the intervention
along with information about their spirometry results.
After 12 months of follow-up, a nonsignificant effect in
favor of the spirometry intervention was observed (RR:
1.17; 95 %CI: 0.66-2.06). More recently, Parkes et al
[23] published a clinical trial that included 561 smokers
recruited in 5 primary care centers in England. All par-
ticipants were assessed using spirometry and then ran-
domized to receive personalized information about the
results obtained, summarized as “lung age” compared
to chronological age (intervention group), or to receive
a letter reporting the results (control group). After
12 months of follow-up, the rates of punctual smoking
abstinence were significantly higher in the intervention
group (13.6 % vs 6.4 % in the control group, p = 0.005)
and these participants had higher probability of successful
smoking cessation than those who did not receive person-
alized spirometry results (RR: 2.12; 95 %CI: 1.24-3.62).
Nonetheless, the observed abstinence rate could have been
influenced by the intensity of the intervention that was ad-
ministered (longer period of contact in the intervention
group due to verbal reinforcement); it has been shown
that abstinence rates are directly proportional to the inten-
sity of the strategy used [24].
In a Cochrane Database of Systematic Reviews article,
Bize et al evaluated those three studies and 12 other
clinical trials that have used various biomarkers as a mo-
tivational strategy for successful smoking cessation [25].
Unfortunately, the designs of the studies included in the
review were so heterogeneous that only two pairs of
studies were sufficiently similar in methodology and
intervention to allow a combined analysis. The authors
also found no evidence of significant benefits from the
use of eCO measurement or spirometry in primary care
to improve success rates for smoking cessation efforts.
Therefore, they conclude that, due to the lack of quality
evidence, it is not possible to establish definitive recom-
mendations about the effectiveness of most approaches
used to evaluate biomedical risk assessment as a means
of helping smokers quit smoking. They emphasize a
need to improve the methodological quality of future
studies. Their review included two active clinical trials
with similar methodology, ESPIROTAB and ESPITAP
[26, 27], that use spirometry results as a motivational
strategy to increase smoking cessation success rates be-
yond the levels obtained by usual counseling, as in the
study by Parkes et al [23]. Nonetheless, this type of study
design has been criticized because, strictly speaking, it
does not provide independent evidence of the effectiveness
of using spirometry, compared to no spirometry; this
would require a trial in which spirometry is not used in
the control group [28].
The use of spirometry as a motivational tool for smoking
cessation continues to be a controversial topic. Some data
indicating effectiveness are encouraging, but the scarcity of
evidence limits the capacity to establish definitive recom-
mendations about its use.
For all these reasons, further studies are essential, and
must use high-quality methodology with a sufficiently
large sample and long-term follow-up of at least 12 months
to establish a final outcome of prolonged smoking abstin-
ence, confirmed by a biochemical method [25].
Hypothesis and objectives
Hypothesis
An intervention based on providing structured, standard-
ized information about the results of spirometry as part of
usual clinical practice to encourage patients to quit smok-
ing will achieve improvement of 5 % or more in the rate of
prolonged abstinence from smoking at 12 months of
follow-up, compared to that obtained by providing only
the usual brief counseling to patients who smoke.
Objectives
The primary objective of this study is to evaluate the ef-
fectiveness of providing structured information about
the results of spirometry testing to increase the rate of
prolonged abstinence from smoking at 12 months after
an anti-smoking intervention in primary care patients
who smoke but do not have a known respiratory disease.
Material and methods
Design
The general framework of the RESET study is shown in
Fig. 1 and the activities to be carried out at each visit are
detailed in Table 1. This is the second phase of the ESPI-
TAP study (Spanish acronym for “Effectiveness of Smok-
ing Cessation Advice Combined With Spirometric Results
in Adult Smokers”), a randomized, controlled, parallel,
multicenter clinical trial in smokers with no history of re-
spiratory disease, recruited when they visited a primary
care center [27].
Setting and study population
The study population will be obtained from patients
who consult any primary care center managed by the
Catalan Institute of Health in the province of Tarragona.
These 20 centers, 12 urban and 8 rural, employ 286
family doctors who care for an adult population (older
than 18 years) of 279,637 patients.
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Participant selection
Eligible participants include all patients aged 35 to
70 years who smoke, who consult their primary care
team during regular office hours for any reason during
the inclusion period, and who meet all inclusion criteria
and none of the exclusion criteria, as follows:
– Inclusion criteria: active cigarette smoker with a
cumulative habit of more than 10 packs/year. An
active smoker is defined as one who acknowledges
having smoked regularly during the past 30 days,
regardless of the quantity. Cumulative consumption
(pack-years) is defined as the value obtained by
multiplying the daily mean of cigarettes smoked by
the number of years as a smoker, divided by 20
cigarettes/pack.
– Exclusion criteria:
1) Any evidence of previous respiratory disease
diagnosis (e.g., COPD, chronic bronchitis,
asthma, bronchiectasis, etc.).
2) Pulmonary function examination within previous
12 months,
Fig. 1 Diagram of the RESET study: process of selection, randomization and follow-up of subjects included in the study
Martin-Lujan et al. BMC Family Practice  (2016) 17:15 Page 4 of 11
3) Any chronic or terminal disorder that, in the
researcher’s opinion, could affect the baseline
parameters or the tests required for the study,
4) Impossibility of follow-up participation for any
reason, and
5) Patient refusal to participate or withdrawal from
the study.
Sample calculation
To achieve the study objective, a sample of 1000 partici-
pants, 500 in each study group (control and intervention),
will be recruited. This will allow the detection of differ-
ences in smoking abstinence greater than or equal to 5 %,
with 95 % CI and 80 % strength in two-tailed tests, assum-
ing an abstinence rate of 5 % to 6 % in the control group
at 12 months and approximately 10 % loss rate during
follow-up [24].
Recruitment, randomization, and data collection (visit 0)
During the selection visit (visit 0), all eligible patients
will be advised that smokers are susceptible to various
diseases related to tobacco use and smoking cessation
will be recommended. They will then be told about the
study and offered the possibility of participating. Those
who agree will be asked to provide signed informed con-
sent and all the necessary data will be collected using an
ad hoc questionnaire that includes:
 Personal and sociodemographic data (age, sex,
marital status, and education level and occupation as
markers of social class)
 History of diseases, comorbidities, and drug treatments
 History of respiratory symptoms
 Lifestyle (alcohol use and physical activity)
 Smoking habit, current and cumulative (packs/year);
nicotine dependence (Fagerström test [29]),
motivation to quit smoking (Richmond test [30]),
and stage of change (precontemplation, contemplation,
preparation, action, maintenance and relapse,
according to Prochaska and DiClemente [31])
 Previous quit attempts (number and therapeutic
resources used)
 Basic physical examination (weight, height, body
mass index, blood pressure)
 eCO levels, measured by MicroCO™ (Micro Medical
Ltd, Rochester, UK); this model detects an eCO
concentration range of 0-100 parts per million
(ppm) with a sensitivity of 1 ppm.
All health professionals working in the 20 primary care
centers included in this study will be eligible to partici-
pate in the selection process.
Randomization
After the selection visit, included participants will be
randomized 1:1 to the intervention or control group.
Table 1 Diagram of activities to be carried out by participants at each visit













Basic physical examination X




Control group: brief health counseling X




Smoking habit X X X
Confirmation of smoking abstinence (coximetry and urine cotinine) X
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The group assignment will be blinded, consecutive, and
centralized at the Tarragona Research Support Unit of the
IDIAP Jordi Gol, and will follow a simple randomization
numeric sequence compiled for this purpose. Of course,
due to the nature of the intervention, researchers and par-
ticipants cannot be blinded to this assignment.
Data collection
Individuals assigned to the intervention group will be
contacted to return to their primary care center for an
evaluation of their pulmonary function using forced spir-
ometry. The test will be carried out by selected nursing
personnel with the appropriate technical skills accredited
by the Health Studies Institute of the Catalan govern-
ment, all using the same standard model of spirometer
(DATOSPIR-600, SIBEL SA, Barcelona, Spain) with a
disposable LILLY-type transducer and following a standard
procedure according to ATS/ERS (American Thoracic Soci-
ety/European Respiratory Society) recommendations [32].
At least three tests will be carried out, from which the
best values will be selected for forced vital capacity
(FVC), expiratory flow in the first second (FEV1), and
ratio of the two measures (FEV1/FVC). Variability between
these two tests should be <5 %, expiration time >6 seconds,
and the start of the test should show an appropriate and
rapid increase. Finally, the reversibility of a possible airway
obstruction will be evaluated by a repeat spirometry test
20-30 minutes after the administration of 400 micrograms
of salbutamol using a space chamber. All of the tests
will be submitted to a single observer, who will
centralize quality control and interpret the results using
computer software.
Description of the intervention (visit 1)
All participants will be contacted for an intervention
(visit 1) that will include a 5-minute session with their
doctor, who will provide health education and advice
about quitting smoking, following the usual recommen-
dations for primary care professionals provided by the
Tobacco Study Group of the Catalan Society of Family
Medicine and the special program, “Atenció Primària
Sense Fum” (in Catalan; “Smoke-Free Primary Care”), as
shown in Table 2. In addition, they will receive information
about the ill effects of tobacco on pulmonary function, il-
lustrated by the Fletcher diagram showing how age-related
loss of lung capacity can be accelerated in smokers and
how this deterioration slows when one quits smoking,
although lost capacity is not recovered [33].
In addition, participants assigned to the intervention
group will receive standardized information about their
spirometry results in a personalized visit lasting about
15 minutes, explaining the content of the report in detail.
The commentary on each spirometry test will be prepared
from a consensus interpretation by the research team, and
will focus on a structured description of the results ob-
tained and their interpretation with reference to a the-
oretical normal value. In addition, the participant will
be informed about the “lung age index”, defined as the
mean age of a nonsmoker with the same FEV1 value),
compared to the chronological age of the participating
smoker. This will illustrate the pulmonary deterioration
that occurs as a consequence of smoking tobacco [34].
Patients with FEV1 and/or FVC values <80 % of the
theoretical reference value and/or FEV1/FVC <0.7 will
be informed and advised to undergo the medical testing
Table 2 Summary of the RESET study control and intervention protocols
Control group: brief anti-smoking intervention Intervention group: spirometry report
In a 5-minute intervention, the health professional will make a clear, firm,
personalized proposal recommending smoking cessation, in an empathic
and respectful manner. He or she will clearly explain to the smoker that
the most important decision the individual can make to achieve better
health is to quit smoking, and will provide written informational materials
that describe the benefits of giving up smoking.
In a 15-minute intervention, the health professional will carry out an
intervention with the same content as the brief anti-smoking intervention
and will provide personalized information about the spirometry results,
clearing up any patient doubts about spirometry or any other questions
that come up during the visit.
The materials are provided by the “Smoke-Free Primary Care” program of
the Catalan Society of Family Medicine and the Public Health Agency of
Catalonia and are regularly used in primary care offices for brief anti-smoking
interventions.
If spirometry values are within normal range, the patient will be informed
that his or her pulmonary function has not yet deteriorated and that this
would be a good time to quit smoking.
If spirometry values indicate airway obstruction (FEV1/FVC <70 %), the
patient will be informed that he or she could have chronic obstructive
pulmonary disease due to smoking, and that the most important
treatment measure is to quit smoking.
If spirometry values show airway restriction, the patient will be informed
that his or her pulmonary function could be affected and will be advised
to continue with the pulmonary tests normally administered in that
primary care center.
In addition, the patient will be informed of his or her lung age (i.e., the
mean age of a nonsmoker with the same FEV1) compared to his or her
chronological age, in order to illustrate the possible deterioration of the
lungs as a result of smoking.
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required to confirm a possible problem with pulmonary
function.
Independently of study group assignment, all partici-
pants who indicate a desire to quit smoking will be offered
the possibility of attending the quit-smoking consultations
that are integrated into the everyday activities at each
center.
Follow-up period (visits 2-3)
All participants will be periodically evaluated by their
regular primary care team. This will include two follow-up
telephone calls, at 3 months (visit 2) and 6 months (visit
3) postintervention, to determine whether they have quit
smoking or have made changes in their smoking habits.
New data will be collected on current consumption or quit
date, if that is the case.
Finally, an in-person visit will be scheduled with each
participant (visit 4) after 12 months have passed since
study inclusion. At this last study visit, data will again be
collected about smoking habits (current consumption,
nicotine dependence, motivation and stage of change),
attempts to quit, and resources and drug therapy used
during the 12-month follow-up. Participants who report
that they have quit smoking will be asked to provide
their quit date, and their non-smoking status will be
confirmed by measuring eCO levels and urine cotinine.
Definition of variables
Outcome measures
The primary outcome variable will be prolonged abstinence
at 12 months postintervention. The secondary variable will
be point-prevalence abstinence at the end of follow-up. The
criterion used to establish the type of abstinence will follow
the recommendations of the Society for Research on
Nicotine and Tobacco [35]:
– Prolonged abstinence, defined as sustained abstinence
from an initial period in which smoking is not
counted as a failure (the recommendation is that
this period not exceed 2 to 4 weeks) until a
follow-up point.
– Point-prevalence abstinence refers to abstinence
during a time window immediately before the
follow-up point (usually 7 days).
Self-reported smoking abstinence will be validated by
biochemical testing at the end of follow-up. Only those
participants who report that they quit smoking and have
eCO levels less than 10 ppm and urine cotinine values less
than 100 ng/mL will be considered nonsmokers [36].
Independent measures
The predictive variables to be analyzed include the
following:
a) Demographic: age, sex, and social class (education
level and occupation)
b) Anthropometric (weight and height) and main
spirometry parameters (FVC, FEV1, and FEV1/FVC%)
c) History of comorbidities and risk factors associated
with tobacco use (hypertension, diabetes mellitus,
ischemic heart disease, cerebrovascular accident,
peripheral arterial disease, etc.)
d) Lifestyles and habits (physical activity, use of alcohol
or other drugs)
e) Characteristics of the smoking habit (accumulated
and current consumption, stage of change
[Prochaska], score on dependency test [Fagerström],
and motivation [Richmond]), previous quit attempts
and reasons for relapse, and use of drug therapy or
other methods to quit smoking during the year of
follow-up.
Data recording and storage
All of the information from the study will be recorded
consistently on an ad hoc questionnaire designed for this
purpose. Each participant will be assigned a personal
identification code upon inclusion, consisting of the ini-
tials of their surnames, sex, and birthdate. All informa-
tion obtained will be stored using an online application
accessible only from the Intranet of the Catalan Health
Institute in Tarragona. Access to this site is restricted
and will be controlled by a personal password for each
investigator, who will be responsible for data entry for all
of the participants he or she recruits. Weekly back-ups
will provide two secure copies of all stored data.
Statistical analysis
Data for the present study were extracted from a central-
ized database and grouped so that the person responsible
for their analysis was blinded to study group assignments.
First, the database was cleansed by detecting and labeling
outlier, missing, and inappropriate values. Next we tested
the effectiveness of the randomization by evaluating the
comparability and homogeneity of the study groups to
ensure similar distribution of the variables of interest at
baseline. Finally, the proportion of participants lost to
follow-up in each group was determined and tested for
any association with the study intervention. All analysis
was based on intention to treat, understood as having
recorded relevant data on the primary variable at the
participant’s first visit. Worst-case analysis was applied
to assess potential bias due to losses to follow-up [37],
which considers that the desired outcome was obtained
by all participants lost to follow-up who were in the
control group and by none of those lost from the interven-
tion group. Having made this assumption, we repeated the
analysis and, to determine the variability associated with
the losses to follow-up, compared the “worst-case” results
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and the results obtained when those lost to follow-up were
not taken into account.
Descriptive analysis of quantitative and qualitative
variables included frequencies, central tendencies (mean
or, in the case of non-normal distribution, median) with
standard deviation, and minimum and maximum values.
Frequencies were compared using chi-square test or
Fisher exact test, as appropriate, and means using Student
t test for independent samples.
To evaluate the effectiveness of the smoking cessation
intervention, rates of punctual and prolonged abstinence
were assessed at 12 months post-intervention in both
groups using the chi-square test. The results were pre-
sented as relative risk (RR), relative risk reduction (RRR)
and absolute risk reduction (RAR) and number needed
to treat (NNT) to achieve prolonged smoking abstinence
in one smoker, expressed with their 95 % confidence
interval (CI). To study the behavior of both groups over
time, log-rank tests were used to compare the cumulated
abstinence curves over the 12-month follow-up. Finally,
multivariate analysis using Cox regression was applied to
study the factors associated with smoking cessation suc-
cess at 12 months. Various models were formulated that
included the variable of interest (the described interven-
tions) and as control variables the factors shown to be
most significant in the literature [38]: age, sex, social
class, employment status, educational level, daily and
cumulated tobacco use, degree of nicotine dependence,
degree of motivation to quit smoking, and stage of change.
All analysis was done using SPSS version 19.0. Sig-
nificance was set at p < 0.05.
Limitations of the study
The study has several potential limitations that must be
taken into consideration. The first cluster is related to the
population. Participants were volunteers recruited when
they visited their primary care team for any reason; there-
fore, they might not be representative of the population of
smokers in the primary care system. In addition, those
who agreed to participate could be more motivated to quit
smoking than the rest of the population of smokers. In
any case, the proposed randomization should ensure
comparability between study groups. As patients will be
recruited by a health care professional with whom they
have an existing relationship, participation is expected
to be high, especially considering that no drug therapies
or invasive or unpleasant tests are involved. Nonetheless,
a certain percentage of losses to follow-up is to be ex-
pected because this is a long-term (12-month) project.
To minimize this contingency, sustained effort by all
participating researchers will be essential to motivating
and encouraging patients.
With respect to limitations of the study design, the
most obvious is that a double-blind study is impossible;
both participants and investigators will necessarily be
aware of the study group assignments. The proposed
intervention may be less intensive than has been de-
scribed in other studies, but reflects the usual attention
received by smokers and therefore can be readily in-
corporated into the daily clinical practice of the inves-
tigators. The content and duration of the intervention
have been standardized and participating doctors and
nurses will receive specific training to ensure that
similar messages, attitudes, and behaviors will be applied
in interactions with both groups. In the spirometry
intervention group, patient collaboration and technical
considerations will be key to achieving quality results.
To maximize quality, the testing will be standardized
by the use of high-quality pneumotachography and by
training of study personnel that results in official accredit-
ation. In addition, to reduce variability in the interpretation
of results, data analysis will be centralized.
Research ethics and confidentiality
The study protocol was approved by the Clinical Re-
search Ethics Committee of IDIAP (Institut Universitari
d’Investigació en Atenció Primària) Jordi Gol (registra-
tion number 4R11/037) and peer-reviewed by the same
experts organization. This trial also has been registered
with ClinicalTrial.gov (NCT02153047) on 28/05/2014.
The principal investigator will ensure that the present
study is carried out in conformity with all pertinent
national and international legislation and with the
principles of the Declaration of Helsinki and the
Guidelines for Good Clinical Practice published by the
Catalan Institute of Health.
All the investigators will use the same standardized
protocols, written manuals, specific guidelines, and ma-
terials to train health-care personnel to deliver uniform
intervention. The protocol will be explained in a training
session for all the investigators, and the coordinating
center will clarify any questions and problems arising in
the course of the study follow-up.
All participants will sign an informed consent prior to
participation in the trial, and will receive general infor-
mation about the study, research objectives and activities
included in study participation, number of primary care
visits, testing that will be done, information about the
results, etc. At all times, data confidentiality will be
guaranteed in accordance with Spanish law on personal
identity and data, both during the study and in the
publication of study results. The instructions provided
by the Catalan Institute of Health with respect to ac-
cess to clinical information for research purposes will
also be followed. Documentation will be stored securely
and will be available only to study personnel who are
authorized to have access.
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Discussion
Data from clinical trials show that increased motiv-
ational tension can be a catalyst that leads a smoker to
begin or maintain smoking abstinence [39]. However,
not all smokers are sufficiently motivated to give up this
habit. They may be afraid of the side effects of abstin-
ence (such as weight gain or increased stress), or think
they are unable to achieve it (if they have a history of
previous relapses), or may simply have no information
about the harmful effects of tobacco or the benefits of
quitting. In these cases, the patient might be likely to re-
spond to a motivational strategy [5].
Health problems are an important motivational factor
to quit smoking and the quit smoking rates seem to be
higher in smokers who fear the health complications re-
lated to smoking [12]. In this context, the evaluation of
individual risk using biomedical tests or assessment of
genetic susceptibility to cancer could help to improve
abstinence rates [25]. These interventions are based on
the idea that informing the smoker about individual risk,
based on personal data, could improve understanding of
the adverse health effects of smoking and increase motiv-
ation to quit smoking [9]. In addition, an individualized
focus using risk assessment tools should allow a more ef-
fective approach, primarily in smokers with the highest
risk and greatest motivation to quit smoking.
This strategy is not new and has been used success-
fully for years in the prevention of coronary diseases
[40]; therefore, in theory it could also apply to a smoking
habit. However, the authors of the Cochrane Review article
that evaluated the effectiveness of informing smokers
about biomedical risks as a way of helping them quit
smoking concluded that few tests are available and no de-
finitive recommendations can be established [5]. This is a
logical conclusion, taking into account the small sample
size of most of the 15 studies included in the review
article, their methodological heterogeneity, and the lack
of benefit detected in each individual study. Only two
trials observed significant effects: Parkes et al [23] used
reinforcement with spirometry results in terms of “lung
age” (RR 2.12; 95 %CI: 1.24-3.62) and Bovet et al [41]
showed participants echocardiographically obtained pho-
tographs of coronary artery plaque (RR 2.77; 95 %CI:
1.04-7.41). The same review indicates that it is possible
to improve the methodological quality of future studies
by adjusting the sample size to the research objectives,
improving the randomization and the process of mak-
ing random, blinded assignments, using the consensus
definitions of “smoker” and “abstinence”, a biochemical
test to confirm smoking abstinence, and an intention-
to-treat statistical approach.
The evaluation of pulmonary function in asymptomatic
smokers is a controversial topic [20]. Although the use
of spirometry has become generalized in our setting, its
usefulness in managing COPD in the initial phases of
the disease has been questioned because quitting smok-
ing is the most important measure that can be taken to
reduce morbidity and mortality; therefore, smoking ces-
sation is an intervention that should always be applied,
independently of a COPD diagnosis [42]. Although
some observational studies have indicated that early
diagnosis of COPD could increase smoking abstinence
rates [16, 19], the effectiveness of spirometry as a motiv-
ational tool has not yet been demonstrated convincingly
in a clinical trial [43]. To the contrary, some doubts
have been raised and there have been suggestions that
providing information about a normal result could have
a “tranquilizing effect” that strengthens the bias of opti-
mism that some smokers have about their own smoking
habit [44]. In any case, and in light of the available data, it
is evident that more research is needed to determine
whether feedback on spirometry data has a differential
impact on smokers depending on the evidence of dete-
riorated pulmonary function.
In this context, the RESET is proposed as a random-
ized, controlled, parallel, multicenter clinical trial that
will include smokers with no known history of respira-
tory disease, with the primary objective of evaluating
whether an intervention based on proving information
about spirometry as a motivational element will improve
the success rates of smoking cessation interventions in
primary care settings. Perhaps the results of the proposed
study will contribute to clarifying some of the uncertain-
ties that currently exist.
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